tiprankstipranks
Advertisement
Advertisement

APRE Stock Latest News

Aprea Therapeutics reports Q2 EPS (7c), consensus (22c)
The FlyAprea Therapeutics reports Q2 EPS (7c), consensus (22c)
7d ago
APRE
Aprea Therapeutics advances APR-1051 oncology pipeline progress
PremiumCompany Announcements
Aprea Therapeutics advances APR-1051 oncology pipeline progress
12d ago
8K
APRE
Aprea Therapeutics: Buy Rating Reiterated as APR-1051 Clinical Momentum Builds; $1.20 Price Target Maintained
PremiumRatings
Aprea Therapeutics: Buy Rating Reiterated as APR-1051 Clinical Momentum Builds; $1.20 Price Target Maintained
14d ago
APRE
Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors
PremiumCompany Announcements
Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors
20d ago
APRE
Aprea Shareholders Approve Directors, Reverse Split Flexibility
PremiumCompany Announcements
Aprea Shareholders Approve Directors, Reverse Split Flexibility
2M ago
8K
APRE
Pantginis Reiterates Buy on APR-1051 Developer, Keeps $1.20 Price Target After Encouraging ASCO Data and Superior Safety Profile
PremiumRatingsPantginis Reiterates Buy on APR-1051 Developer, Keeps $1.20 Price Target After Encouraging ASCO Data and Superior Safety Profile
3M ago
APRE
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target
Premium
Ratings
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target
3M ago
APRE
Aprea Therapeutics price target lowered to $6 from $7 at Wedbush
Premium
The Fly
Aprea Therapeutics price target lowered to $6 from $7 at Wedbush
3M ago
APRE
Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year
PremiumThe Fly
Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year
3M ago
APRE
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress
PremiumCompany Announcements
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress
3M ago
8K
APRE
Oracle upgraded, Planet Fitness downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Oracle upgraded, Planet Fitness downgraded: Wall Street’s top analyst calls
4M ago
ABX
CNH
Aprea Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe Fly
Aprea Therapeutics initiated with an Outperform at Oppenheimer
4M ago
APRE
Aprea Therapeutics files to sell 74.35M shares of common stock for holders
PremiumThe FlyAprea Therapeutics files to sell 74.35M shares of common stock for holders
4M ago
APRE
Aprea Therapeutics: Positive Read‑Through From Zentalis and Improving WEE1 Sentiment Support Buy Rating and $5 Target
Premium
Ratings
Aprea Therapeutics: Positive Read‑Through From Zentalis and Improving WEE1 Sentiment Support Buy Rating and $5 Target
4M ago
APRE
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
Premium
Company Announcements
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
5M ago
8K
APRE
Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
PremiumThe Fly
Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
5M ago
APRE
Aprea Therapeutics Announces $30 Million Private Placement
PremiumCompany Announcements
Aprea Therapeutics Announces $30 Million Private Placement
5M ago
8K
APRE
Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial
PremiumThe Fly
Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial
5M ago
APRE
Aprea Highlights Early APR-1051 Data and Financial Update
PremiumCompany Announcements
Aprea Highlights Early APR-1051 Data and Financial Update
5M ago
8K
APRE
Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
PremiumThe FlyAprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
5M ago
APRE
Aprea Therapeutics sees cash runway into 1Q27
Premium
The Fly
Aprea Therapeutics sees cash runway into 1Q27
5M ago
APRE
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
Premium
The Fly
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
6M ago
APRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >